medigraphic.com
ISSN 1560-4381 (Print)

2019, Number 4

<< Back Next >>

Correo Científico Médico 2019; 23 (4)

Multi-drug resistance in tuberculosis. Case report

Leyva RKM, Luaces LR, Riverón PI, Osorio SE, González LM

Language: Spanish
References: 16
Page:
PDF size: 359.37 Kb.


ABSTRACT

Tuberculosis is an increasing global health problem, and the antibiotic resistance an element for concern. A 53 year-old patient was admitted at the emergency department for presenting hemoptysis. There were antecedents of pulmonary tuberculosis with irregular treatment. Multidrug-resistant tuberculosis was documented. Different strategies with available medical treatment were considered with the following drugs: prothionamide, p-aminosalicylic acid, pyrazinamide, terizidone, and moxifloxacin. Due to high epidemiological risk and records of poor response to previous medications, he underwent an in-hospital treatment but the results were not satisfactory. The patient perishes from respiratory insufficiency right after 2 weeks of clinical deterioration. Later, the necropsy examination revealed as the cause of death bilateral pneumonia of tuberculous etiology.


REFERENCES

  1. Martínez Romero MR, Sardiña Aragón M, García León G, Mederos Cuervo LM, Díaz Rodríguez R. Nuevas herramientas para el diagnóstico de la tuberculosis. Rev Cubana Med Trop. 2015 [citado 27 may 2019]; 67(1):41-49. Disponible en: http://scielo.sld.cu/pdf/mtr/v67n1/mtr05115.pdf

  2. Dombret DC. Tuberculosis pulmonar en el adulto.EMC.2018 [citado 2 oct 2019];22(1). Disponible en: https://www.sciencedirect.com/science/article/pii/S1636541017878739?via%3Dihub

  3. Pai M, Temesgen Z. Quality: The missing ingredient in TB care and control. J Clin Tuberc Other Mycobact Diseases. 2019 [citado 2 oct 2019]; 14(3):12-13. Disponible en: https://www.clinicalkey.es/#!/content/journal/1-s2.0-S2405579418300846

  4. MINSAP. Programa Nacional de Control de la Tuberculosis. Resolución Ministerial 277. La Habana: MINSAP; 2014[citado 27 sep 2019]. Disponible en: http://www.sld.cu/galerias/pdf/sitios/tuberculosis/programa_2015.pdf

  5. Palmero DJ, Laniado Laborína R, Caminero Luna JA. Asociación Latinoamericana de tórax. Guías latinoamericanas de diagnóstico y tratamiento de la tuberculosis fármacorresistente. Arch Bronconeumol. 2013. [citado 2 oct 2019]; 44 (10). 578. Disponible en: https://www.archbronconeumol.org/es-guias-latinoamericanas-diagnostico-tratamiento-tuberculosis-articulo-S0300289608759015

  6. Udwadia Z, Furin J. Quality of drug-resistant tuberculosis care: Gaps and solutions. J Clin Tuber Other Mycobacter Diseases.2019 [citado 2 oct 2019]; 16: 100101. Disponible en: https://www.clinicalkey.es/#!/content/1-s2.0-S2405579419300361

  7. WHO. Global tuberculosis report 2019. Geneva: WHO;17 oct 2019. [citado 20 oct 2019]. Disponible en: https://www.who.int/tb/publications/global_report/en/

  8. WHO. WHO guidelines on tuberculosis infection prevention and control: 2019 update. Geneva: WHO; 13 mar 2019 [citado 3 oct 2019]. Disponible en: https://apps.who.int/iris/handle/10665/311259

  9. Lemus Molina D, Álvarez Echaide Y, Echemendía Font M, Van der Stuyft P, Palomino JC, Martin A. Utilidad del método de la nitrato reductasa para la detección de resistencia a drogas antituberculosas de segunda línea. Rev Cubana Med Trop .2015 [citado 27 may 2019];67(1):20-27. Disponible en: http://scielo.sld.cu/pdf/mtr/v67n1/mtr03115.pdf

  10. GBD Tuberculosis Collaborators. Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. Lancet Infect Dis. 2018 [citado 20 sep 2018]; 18(12):1329–1349. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250050/pdf/main.pdf

  11. Caminero JA, Cayla JA, García García JM, García Pérez FJ, Palacios JJ, Ruiz Manzano J. Diagnóstico y tratamiento de la tuberculosis con resistencia a fármacos. Arch Bronconeumol. 2017[citado 20 sep 2019]; 53(9):501–509. Disponible en: https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0300289617300509.pdf?locale=es_ES

  12. Chiang CY, Van Deun A, Trébucq A, Piubello A, Schwoebel V, Rieder HL. Multidrug-resistant tuberculosis. Lancet. 2019[citado 20 sep 2019];394(10195):299.Disponible en: https://www.sciencedirect.com/science/article/pii/S0140673619300467

  13. Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 2018. [citado 20 de sept 2019];392(10150):821-834. Disponible en: https://www.sciencedirect.com/science/article/pii/S0140673618316441

  14. Lemus D, Echemendía M, Díaz R, Llop A, Josefa Llanes M. Vigilancia de la resistencia a los fármacos antituberculosos en Cuba.2010-2011. Biomédica. 2014 [citado 29 sep 2019]; 34(Supl 1):108-113. Disponible en: https://revistabiomedica.org/index.php/biomedica/article/view/2199/2375

  15. Seaworth BJ, Griffith DE. Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Microbiol Spectr. 2017[citado 3 oct 2019]; 5(2). Disponible en: https://www.asmscience.org/content/journal/microbiolspec/10.1128/microbiolspec.TNMI7-0042-2017

  16. Caminero Luna JA. Actualización en el diagnóstico y tratamiento de la tuberculosis pulmonar. Rev Clin Española. 2016[citado 20 sep 2018]; 216(2):76-84. Disponible en: https://www.clinicalkey.es/service/content/pdf/watermarked/1-s2.0-S0014256515002301.pdf?locale=es_ES




2020     |     www.medigraphic.com